CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 241 enrolled
Drug / intervention
CoreValve Evolut R TAVR systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02207569
NCT02207569N/ACompleted
CompareCT.gov

Medtronic CoreValve Evolut R United States IDE Clinical Study

Medtronic Cardiovascular·interventional·Posted Aug 4, 2014·Updated Nov 2, 2022

In Brief

A clinical study evaluating CoreValve Evolut R TAVR system for Aortic Stenosis. Completed, enrolled 241 participants across 23 sites.

Detailed Summary

The study objectives are to assess the safety and efficacy of the CoreValve Evolut R transcatheter aortic valve replacement (TAVR) system in patients with severe symptomatic aortic stenosis are considered at high or extreme risk for surgical aortic valve replacement.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAortic Stenosis
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 4, 2014
Enrollment StartAug 1, 2014
Primary CompletionAug 1, 2015
Study CompletionOct 28, 2020
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 11.9 years ago

Interventions

CoreValve Evolut R TAVR systemdevice